Case Name: In re: Suboxone (Buprenorphine Hydrochloride and Nalaxone) Antitrust Litigation
Docket No.: 2:13-md-02445
filed:March 1, 2013
court:U.S. District Court, Eastern District of Pennsylvania
The Suboxone case was filed in the Middle District of Pennsylvania on March 1, 2013. All related actions were then consolidated and transferred to the Eastern District of Pennsylvania. Suboxone is a combination drug product for the maintenance treatment of opioid dependence.
The Suboxone complaint alleges that the brand manufacturer used a series of anticompetitive tactics to thwart generic competition, which included: “product hopping” from a tablet to a film formulation, destroying demand for its own tablet by raising its price and publically announcing safety concerns (no legitimate safety concern was found by the FDA); and filing baseless “sham” citizen petitions with the FDA to delay lower priced generic tablets from reaching the market. Due to this anticompetitive scheme, consumers have been robbed of the benefits of generic competition to the tune of at least some $500 million annually.